Status:
COMPLETED
Faslodex Registry: Fulvestrant in Current Clinical Practice
Lead Sponsor:
AstraZeneca
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
Brief Summary
The sequential administration of endocrine therapies to patients with advanced breast cancer requires the availability of therapies with different modes of actions, so that tumours developing resistan...
Eligibility Criteria
Inclusion
- Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer
Exclusion
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00735215
Start Date
October 1 2008
End Date
December 1 2009
Last Update
December 23 2009
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Antwerp, Belgium
2
Research Site
Bruges, Belgium
3
Research Site
Brussels, Belgium
4
Research Site
Ghent, Belgium